

Concentrations of ciprofloxacin in the world's rivers are associated with the prevalence of fluoroquinolone resistance in *E. coli*: a global ecological analysis

Chris Kenyon^{1,2*}

¹HIV/STI Unit, Institute of Tropical Medicine, Antwerp, Belgium; ²Division of Infectious Diseases and HIV Medicine, University of Cape Town, Anzio Road, Observatory 7700, South Africa

*Corresponding author. HIV/STI Unit, Institute of Tropical Medicine, Antwerp, 2000, Belgium. Tel: +32 3 2480796; Fax: +32 3 2480831; E-mail: ckenyon@itg.be

Running title: Concentration of ciprofloxacin in the world's rivers

Word count: Text: 1192 words, Abstract: 116 words

Abstract

Background

Extremely low concentrations of ciprofloxacin may select for antimicrobial resistance. A recent global survey found that ciprofloxacin concentrations exceeded safe levels at 64 sites. We assessed if national median ciprofloxacin concentrations in rivers were associated with fluoroquinolone resistance in *Escherichia coli*.

Methods

Spearman's regression was used to assess the country-level association between the national prevalence of fluoroquinolone resistance in *E. coli* and the median ciprofloxacin concentration in the countries rivers.

Results

The prevalence of fluoroquinolone resistance in *E. coli* was positively correlated with the concentration of ciprofloxacin in rivers ($\rho=0.36$; $P=0.011$; $N=48$).

Conclusions

Steps to reducing the concentrations of fluoroquinolones in rivers may help prevent the emergence of resistance in *E. coli* and other bacterial species.

Keywords: Rivers, one-health, *E. coli*, fluoroquinolones, antimicrobial resistance, AMR

Background

The reasons underpinning the global variations in fluoroquinolone resistance in gram-negative bacteria are incompletely understood [1-3]. Whilst human consumption of quinolones plays an important role, much of the variation remains unexplained with recent analyses suggesting that various socio-economic factors play a critical role [1, 4, 5]. For example, studies have found that better infrastructure such as improved sanitation and potable water were significantly associated with lower antimicrobial resistance (AMR) indices [1, 5].

A relatively unexplored pathway towards AMR in gram-negatives is antimicrobial exposure in ambient water bodies [6, 7]. A number of studies have found that extremely low concentrations of antimicrobials can select for de-novo AMR and enrichment of resistant versus susceptible strains in a range of gram-negative bacteria including *Escherichia coli* [8-10]. The lowest concentration of an antimicrobial that selects for resistant over susceptible strains in competition assays is referred to as the minimum selection concentration (MSC) [8, 10, 11]. In the case of *E. coli*, the ciprofloxacin MSC is 230-fold lower than the minimum inhibitory concentration (MIC) [8].

The appreciation that the MSC is considerably lower than the MIC has lead experts to recommend that the maximum concentration of antimicrobials allowed in water should be approximately 10- to 100-fold lower than the lowest minimum inhibitory concentrations (MICs) of bacteria present in large datasets such as that of EUCAST [6, 9].

Whilst a number of studies have found that high concentrations of antimicrobials in ambient water are associated with AMR in various bacterial species in the environment [7, 12, 13], few studies have found an association with AMR in bacteria present in humans. One exception is a study that found that surfers are have a higher carriage of CTX-M-producing *E. coli* than non-surfers and that the likely exposure was ingestion of water whilst surfing [14]. *E. coli* is a particularly relevant species to test because of its faeco-oral transmission and the fact that it is one of the commonest bacterial causes of diarrhoea worldwide [15].

In this study we assess if there is a country-level association between the prevalence of fluoroquinolone resistance in *E. coli* and the concentration of ciprofloxacin in river water. To do this, we make use of a recently published global survey of pharmaceuticals in the world's rivers that found high levels of ciprofloxacin at numerous sites [6]. This survey used a standard collection and assay to measure the concentrations of 61 active pharmaceutical ingredients at over one thousand locations on 258 of the world's rivers in 104 countries [6]. This included the quinolone antimicrobial ciprofloxacin. One of their most striking findings was that the concentration of ciprofloxacin exceeded the proposed safe limit at 64 sites. We used Spearman's correlation to compare concentrations of ciprofloxacin with the prevalence of *E. coli* resistance to ciprofloxacin from a global database.

Methods

Data

Antimicrobial Resistance Data

The prevalence of *Escherichia coli* fluoroquinolone resistance per country was obtained from the Center for Disease Dynamics, Economics & Policy's (CDDEP) ResistanceMap database. <https://resistancemap.cddep.org/AntibioticResistance.php> CDDEP obtains and aggregates data on the prevalence of antibiotic resistance from several sources. The data are then harmonized to present similar definitions of resistance across countries and regions to enable comparisons between countries. For additional details as to the methodology and definitions used to define antimicrobial resistance please see STable 1 and [16]. The CDDEP data provides a resistance prevalence estimate from a single year for each country, which is typically the year 2017.

Quinolone concentrations in rivers

Wilkinson et al. used a standard collection and assay to measure the concentration of a number of pharmaceutical agents including ciprofloxacin at 1,052 locations on 258 of the world's rivers in 104 countries [6]. In brief, between February 2018 and January 2020, they mailed a standard collection kit to collaborators in 104 countries and asked them to follow a standard sample collection protocol. The sampling sites typically included sites upstream, within and downstream from a populated area. The samples

were kept frozen after collection until they were sent frozen via air shipment to a single analytical center in the United Kingdom for analysis using a single analytical method (high-pressure liquid chromatography-tandem mass spectrometry). We used their data to calculate the median ciprofloxacin concentration per country. The assay used had a limit of detection of 10.1 ng/L for ciprofloxacin. A value of 0 ng/L was used for all sites where the concentration of ciprofloxacin was measured to be below the limit of detection.

Statistical Analyses

Spearman's regression was used to assess the country-level association between the national prevalence of fluoroquinolone resistance in *E. coli* and the median ciprofloxacin concentration in the countries rivers. Statistical analyses were performed in Stata 16.0 and a p-value of <0.05 was regarded as statistically significant.

Results

Ciprofloxacin concentration and resistance data was available from 104 and 58 countries, respectively. Forty-eight countries had data available for both variables. In these 48 countries the prevalence of both fluoroquinolone resistance (median 29%, IQR 20.5-45.5%) and ciprofloxacin concentrations in rivers (median 0 ng/L, IQR 0-45.3 ng/L) varied considerably between countries (Table 1; Fig. 1).

Spearman's correlations

The prevalence of fluoroquinolone resistance in *E. coli* was positively correlated with the concentration of ciprofloxacin in rivers ($\rho=0.36$; $P=0.011$; $N=48$).

Discussion

In this global ecological study we found a positive correlation between the concentration of ciprofloxacin in countries' rivers and the prevalence of fluoroquinolone resistance in *E. coli*. A number of pathways could explain this association. Countries with high ciprofloxacin concentrations in their rivers may consume more ciprofloxacin and this higher consumption may result in both AMR in *E. coli* in humans and higher concentrations of ciprofloxacin excreted and hence detected in rivers [7]. Similarly, these countries may use more fluoroquinolones for animal husbandry and this may generate AMR in *E. coli* in animals that can be

transmitted to humans as well as being excreted into rivers [17, 18]. Studies have found positive associations between the prevalence of fluoroquinolone resistance in *E. coli* in humans and *E. coli* from poultry and pigs [19]. A systematic review performed on this topic found that fluoroquinolone resistance could be transferred from *E. coli* in food-producing animals to humans [20]. Finally, the low levels of ciprofloxacin in rivers may be selecting for AMR in *E. coli* which are then ingested by humans. Our ecological study is unable to disentangle which of these pathways is predominant.

Further limitations of our study include the fact that we do not have longitudinal, individual level or experimental data, the fact that the exposure variable post dates the outcome variable, the small number of countries with resistance data and the relatively low number and non-representativity of sites per country used to establish ciprofloxacin concentrations. The limit of detection for ciprofloxacin was fairly high which may have introduced a bias by assuming all sites with ciprofloxacin undetectable had a concentration of 0ng/L. The fluoroquinolone resistance prevalence estimates from CDDEP are based on a number of different methodologies making comparisons between countries sub-optimal. We were not able to adjust our analyses for either differences in susceptibility testing strategies or breakpoints between countries as CDDEP does not provide this information.

Finally, we did not control for a number of potential confounders in the relationship between ciprofloxacin concentration and resistance such as inadequate processing of sewage, poor sanitation, inadequate regulation of antimicrobials, consumption of other classes of antimicrobials and variations in environmental temperatures [1, 2, 21-25].

Despite these limitations, this ecological study provides motivation for additional research to define safe upper limits for antimicrobials in rivers and ground water. This research should include in-vitro MSC-determination assays that go beyond the 3 to 7 days currently assessed and include stochastic variations in antimicrobial exposure [7, 11]. Finally they should include assessments of the recently established minimum increased persistence concentration (MIPC) which may result in the enrichment of resistance well below MSC concentrations [11].

Acknowledgements

We would like to thank CDDEP for the data provided.

Authors' contributions

CK conceptualized the study. CK was responsible for the acquisition, analysis and interpretation of data. CK read and approved the final draft.

Consent for publication

Not applicable

Data availability

The data we used is publicly available from:
<https://resistancemap.cddep.org/AntibioticResistance.php>

Funding

No specific funding was received for this work.

Competing interests

None to declare. All the authors declare that they have no conflicts of interest.

Table 1. Country-level concentration of ciprofloxacin (ng/L) in rivers and percent of *Escherichia coli* isolates obtained from human infections that are resistant to fluoroquinolones


Country	Year ^a	N sites tested ^b	Ciprofloxacin concentration (median, ng/L)	Ciprofloxacin concentration (mean, ng/L)	<i>E. coli</i> fluoroquinolone resistance (%)
Australia	2017	0	0	0	12
Austria	2017	2	58.7	58.7	22
Belgium	2017	2	66.8	66.8	25
Bulgaria	2017	0	0	0	43
Canada	2014	0	0	0	21
Chile	2014	0	0	0	29
China	2017	4	330.5	329.5	56
Croatia	2017	0	0	0	29
Cyprus	2018	3	47.9	59.8	44
Czech Republic	2017	7	21.5	22.8	26
Denmark	2017	0	0	0	14
Estonia	2017	0	0	0	20
Finland	2017	4	33.5	41	14
France	2017	0	0	0	17
Germany	2017	4	63.2	96.9	23
Ghana	2016	1	122	122	59
Greece	2017	0	0	0	34
Hungary	2017	0	0	0	31
Iceland	2017	0	0	0	14
India	2017	6	275.2	303.3	84
Ireland	2017	0	0	0	26
Italy	2017	0	0	0	47
Japan	2017	0	0	0	30
Kenya	2015	7	67.3	78.2	58
Latvia	2017	0	0	0	32
Lithuania	2017	0	0	0	28
Malaysia	2017	10	42.7	52.8	26
Mexico	2015	3	32.6	26.7	62
Netherlands	2017	0	0	0	16
New Zealand	2015	0	0	0	10
Nigeria	2017	8	102.2	144.8	76
Norway	2017	0	0	0	16
Pakistan	2017	4	51.1	52.0	59
Philippines	2017	0	0	0	39
Poland	2017	1	193	193	38

Portugal	2017	4	98.7	99.0	30
Romania	2017	0	0	0	28
Russia	2017	0	0	0	63
Slovenia	2017	0	0	0	26
South Africa	2016	0	0	0	28
South Korea	2017	0	0	0	37
Spain	2017	0	0	0	33
Sri Lanka	2009	0	0	0	59
Sweden	2017	0	0	0	17
Switzerland	2017	0	0	0	19
Thailand	2017	0	0	0	47
Tunisia	2017	0	0	0	19
Turkey	2016	0	0	0	55

^a Year for E. coli resistance prevalence study

^b Number of sites tested to establish ciprofloxacin concentration in rivers

Fig. 1. Scatter plot of national median concentration of ciprofloxacin in rivers (ng/L) versus prevalence of *Escherichia coli* fluoroquinolone resistance (%)



References

1. Collignon P, Athukorala P-c, Senanayake S, Khan F. Antimicrobial resistance: the major contribution of poor governance and corruption to this growing problem. *PLoS one*. 2015;10(3):e0116746.
2. Chereau F, Opatowski L, Tourdjman M, Vong S. Risk assessment for antibiotic resistance in South East Asia. *Bmj*. 2017;358.
3. Gu B, Cao Y, Pan S, Zhuang L, Yu R, Peng Z, et al. Comparison of the prevalence and changing resistance to nalidixic acid and ciprofloxacin of *Shigella* between Europe–America and Asia–Africa from 1998 to 2009. *Int J Antimicrob Ag*. 2012;40(1):9-17.
4. Collignon P, Beggs JJ. Socioeconomic Enablers for Contagion: Factors Impelling the Antimicrobial Resistance Epidemic. *Antibiotics-Basel*. 2019;8(3). doi: ARTN 86 10.3390/antibiotics8030086. PubMed PMID: WOS:000489181000002.
5. Collignon P, Beggs JJ, Walsh TR, Gandra S, Laxminarayan R. Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. *Lancet Planet Health*. 2018;2(9):e398-e405. Epub 2018/09/05. doi: 10.1016/S2542-5196(18)30186-4. PubMed PMID: 30177008.
6. Wilkinson JL, Boxall ABA, Kolpin DW, Leung KMY, Lai RWS, Galban-Malagon C, et al. Pharmaceutical pollution of the world's rivers. *Proc Natl Acad Sci U S A*. 2022;119(8). Epub 2022/02/16. doi: 10.1073/pnas.2113947119. PubMed PMID: 35165193.
7. Baquero F, Martínez J-L, Cantón R. Antibiotics and antibiotic resistance in water environments. *Current opinion in biotechnology*. 2008;19(3):260-5.
8. Gullberg E, Cao S, Berg OG, Ilbäck C, Sandegren L, Hughes D, et al. Selection of resistant bacteria at very low antibiotic concentrations. *PLoS Pathog*. 2011;7(7):e1002158.
9. Bengtsson-Palme J, Larsson DG. Concentrations of antibiotics predicted to select for resistant bacteria: Proposed limits for environmental regulation. *Environ Int*. 2016;86:140-9. Epub 2015/11/23. doi: 10.1016/j.envint.2015.10.015. PubMed PMID: 26590482.
10. Gullberg E, Albrecht LM, Karlsson C, Sandegren L, Andersson DI. Selection of a multidrug resistance plasmid by sublethal levels of antibiotics and heavy metals. *MBio*. 2014;5(5).
11. Stanton IC, Murray AK, Zhang L, Snape J, Gaze WH. Evolution of antibiotic resistance at low antibiotic concentrations including selection below the minimal selective concentration. *Communications biology*. 2020;3(1):1-11.
12. Sapkota AR, Curriero FC, Gibson KE, Schwab KJ. Antibiotic-resistant enterococci and fecal indicators in surface water and groundwater impacted by a concentrated swine feeding operation. *Environmental Health Perspectives*. 2007;115(7):1040-5.
13. Watkinson A, Micalizzi G, Bates J, Costanzo S. Novel method for rapid assessment of antibiotic resistance in *Escherichia coli* isolates from environmental waters by use of a modified chromogenic agar. *Applied and Environmental Microbiology*. 2007;73(7):2224-9.
14. Leonard AF, Zhang L, Balfour AJ, Garside R, Hawkey PM, Murray AK, et al. Exposure to and colonisation by antibiotic-resistant *E. coli* in UK coastal water users: Environmental surveillance, exposure assessment, and epidemiological study (Beach Bum Survey). *Environment international*. 2018;114:326-33.
15. Shah N, DuPont HL, Ramsey DJ. Global etiology of travelers' diarrhea: systematic review from 1973 to the present. *The American journal of tropical medicine and hygiene*. 2009;80(4):609-14.
16. The Center for Disease Dynamics Economics & Policy. ResistanceMap: Antibiotic resistance. 2021 [cited 2021]. Available from: 2021. <https://resistancemap.cddep.org/AntibioticResistance.php>.
17. ECDC/EFSA/EMA. ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in

- bacteria from humans and food-producing animals: Joint Interagency Antimicrobial Consumption and Resistance Analysis (JIACRA) Report. *Efsa J.* 2017;15(7). doi: UNSP 4872
10.2903/j.efsa.2017.4872. PubMed PMID: WOS:000406685200007.
18. Kenyon C. Positive Association between the Use of Quinolones in Food Animals and the Prevalence of Fluoroquinolone Resistance in *E. coli* and *K. pneumoniae*, *A. baumannii* and *P. aeruginosa*: A Global Ecological Analysis. *Antibiotics.* 2021;10(10):1193.
 19. Vieira AR, Collignon P, Aarestrup FM, McEwen SA, Hendriksen RS, Hald T, et al. Association between antimicrobial resistance in *Escherichia coli* isolates from food animals and blood stream isolates from humans in Europe: an ecological study. *Foodborne pathogens and disease.* 2011;8(12):1295-301.
 20. Muloi D, Ward MJ, Pedersen AB, Fevre EM, Woolhouse ME, van Bunnik BA. Are food animals responsible for transfer of antimicrobial-resistant *Escherichia coli* or their resistance determinants to human populations? A systematic review. *Foodborne pathogens and disease.* 2018;15(8):467-74.
 21. Song J. Antimicrobial resistance control in Asia. *AMR control.* 2015:41-5.
 22. Collignon P, Beggs JJ, Walsh TR, Gandra S, Laxminarayan R. Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. *The Lancet Planetary Health.* 2018;2(9):e398-e405.
 23. Yam ELY, Hsu LY, Yap EP, Yeo TW, Lee V, Schlundt J, et al. Antimicrobial Resistance in the Asia Pacific region: a meeting report. *Antimicrob Resist Infect Control.* 2019;8:202. Epub 2020/01/01. doi: 10.1186/s13756-019-0654-8. PubMed PMID: 31890158; PubMed Central PMCID: PMC6921568.
 24. Lundborg CS, Tamhankar AJ. Antibiotic residues in the environment of South East Asia. *Bmj.* 2017;358.
 25. European Food Safety Authority. The European Union Summary Report on Antimicrobial Resistance in zoonotic and indicator bacteria from humans, animals and food in 2018/2019. *Efsa J.* 2021;19(4).